Market Overview

UPDATE: Johnson & Johnson Posts Upbeat Q2 Earnings, Lifts Outlook

Related JNJ
Facebook, Google Make Glassdoor's List Of Top 50 Places To Work
Karyopharm Therapeutics' Top Execs Talk Recent Results In Multiple Myeloma And Acute Myeloid Leukemia
Dividend Growth - Size Matters ... A Lot! (Seeking Alpha)

Johnson & Johnson (NYSE: JNJ) reported a rise in its second-quarter earnings and lifted its profit forecast for the full year.

The New Brunswick, New Jersey-based company posted a quarterly profit of $4.3 billion, or $1.51 per share, compared to $3.8 billion, or $1.33 per share, in the year-ago period. Excluding certain items, Johnson & Johnson's adjusted earnings came in at $1.66 per share.

Its revenue climbed 9.1% to $19.5 billion. However, analysts were expecting earnings of $1.55 per share on revenue of $19 billion.

For the full-year, Johnson & Johnson's raised its adjusted earnings outlook to $5.85 to $5.92 per share from its earlier forecast of $5.80 to $5.90 per share.

Worldwide consumer sales rose 2.4% y/y to $3.7 billion in the quarter, while worldwide pharmaceutical sales climbed 21.1% to $8.5 billion.

Worldwide medical devices and diagnostics sales increased 0.7% to $7.2 billion in the quarter. Johnson & Johnson's world-wide Olysio sales surged to $831 million in the quarter, up from $354 million in the first quarter.

Alex Gorsky, Chairman and Chief Executive Officer said, "Our strong second-quarter results reflect the continued success of our new product launches and the progress we have made in achieving our near-term priorities."

Johnson & Johnson shares gained 0.11% to $105.50 in pre-market trading.

Posted-In: profitEarnings News


Related Articles (JNJ)

View Comments and Join the Discussion!